Saga, Ladyneth N.

HRN: 11-31-73  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2023
CO-AMOXICLAV 625MG (TAB)
11/30/2023
12/06/2023
ORAL
625mg
BID
NSVD With Perineal Laceration
Checking Final Appropriateness 

Indication:  ProphylaxisEmpiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: